Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.…
29,990$
-1,38%
Echtzeit-Aktienkurs Ideaya Biosciences Inc.
Bid:
Ask:
Nachrichten zur Ideaya Biosciences Inc. Aktie
Stocks making the biggest moves midday: Paramount Global, Morphic Holding, Ideaya Biosciences and more
These are the stocks posting the largest moves in midday trading.…
Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
…
Ideaya Biosciences: A Strong Bet In Targeted Oncology
…
IDEAYA Biosciences reveals 2024 guidance and updates By Investing.com
IDEAYA Biosciences reveals 2024 guidance and updates…
Ideaya Biosciences Stock: An Opportunity Missed (Rating Downgrade)
…
Hepion Pharmaceuticals, Ideaya Biosciences among top healthcare movers
…
IDEAYA Biosciences down 9%, prices $125M offering
…
Insiderhandel: Chief Financial Officer verkauft Aktien von Ideaya Biosciences im Wert von 25.819$
Stone, Paul A. - Vorstand - Tag der Transaktion: 2023-08-21...…
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101
LONDON (dpa-AFX) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application…
IDEAYA wins key milestone in GSK deal as FDA clears cancer trial
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to…
Insiderhandel: Chief Legal Officer verkauft Aktien von Ideaya Biosciences im Wert von 218.178$
Throne, Jason - Vorstand - Tag der Transaktion: 2023-07-10...…
Form 8-K IDEAYA Biosciences, Inc. For: Jun 29
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K IDEAYA Biosciences, Inc. For: Jun 06
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K IDEAYA Biosciences, Inc. For: Jun 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Chief Legal Officer verkauft Aktien von Ideaya Biosciences im Wert von 81.792$
Throne, Jason - Vorstand - Tag der Transaktion: 2023-06-01...…
Insiderhandel: Chief Legal Officer verkauft Aktien von Ideaya Biosciences im Wert von 9.938$
Throne, Jason - Vorstand - Tag der Transaktion: 2023-05-31...…
IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., May 30, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed…
Goldman Sachs Initiates Coverage of Ideaya Biosciences With Buy Recommendation
Goldman Sachs has initiated coverage of Ideaya Biosciences with a Buy recommendation....…
Insiderhandel: Chief Legal Officer verkauft Aktien von Ideaya Biosciences im Wert von 11.500$
Throne, Jason - Vorstand - Tag der Transaktion: 2023-05-22...…
IDEAYA: FDA Approves To Proceed With Evaluation Of IDE397 In Combination With AMG 193
THOUSAND OAKS (dpa-AFX) - IDEAYA Biosciences, Inc. (IDYA) announced the FDA has completed its review of the Amgen-sponsored Investigational New…
Ideaya announces FDA nod to run Amgen-sponsored tumor study
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Announces Amended Clinical Trial Collaboration And Supply Agreements With Pfizer
NEW YORK CITY (dpa-AFX) - IDEAYA Biosciences, Inc. (IDYA) has amended its clinical trial collaboration and supply agreements with Pfizer…
Ideaya, Pfizer amend clinical trials supply contacts for darovasertib, Xalkori for eye cancer
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Biosciences GAAP EPS of -$0.49 beats by $0.03, revenue of $7.88M beats by $2.5M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of March 31, 2023 supplemented by…
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its…
IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event
SOUTH SAN FRANCISCO, Calif., May 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed…
IDEAYA Biosciences up 3%, prices $175M offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?
IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in…
IDEAYA Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif., April 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten…
IDEAYA announces $150M stock offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., April 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to…
IDEAYA jumps 25% after update on lead program
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Shares Rise About 25% as Co. Releases Data From MUM Trial
IDEAYA Shares Rise About 25% as Co. Releases Data From MUM Trial...…
IDEAYA Biosciences shares jump on melanoma interim trial results
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Biosciences Touts Encouraging Data From Combo Therapy For Rare Eye Cancer Impacting Around 14,000 In US and Europe
read more...…
IN8bio, IDEAYA top healthcare gainers; Scilex, EyePoint among losers
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Biosciences Shares Rally Premarket After Darovasertib Update >IDYA
IDEAYA Biosciences Shares Rally Premarket After Darovasertib Update >IDYA...…
Ideaya Biosciences upgraded to buy from hold at Stifel Nicolaus
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K IDEAYA Biosciences, Inc. For: Apr 23
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event
SOUTH SAN FRANCISCO, Calif., April 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed…
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 31, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed…
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.28% and 48.44%, respectively, for the quarter ended December 2022.…
IDEAYA Biosciences GAAP EPS of -$0.50 beats by $0.06, revenue of $4.02M misses by $2.98M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update
Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to…
IDEAYA Biosciences to Participate in Investor Conferences in March 2023
SOUTH SAN FRANCISCO, Calif., March 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine…
IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine…
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
- Initiated Phase 2 clinical trial evaluating Darovasertib as neoadjuvant treatment of uveal melanoma prior to primary interventional treatment of…